This presentation will cover WuXi Biologics’ new biopharmaceutical contract manufacturing facility in Dundalk, Ireland, which has set industry benchmarks in time to market, scale, and flexibility. A unique approach to the process scope of supply was a key factor in this achievement. WuXi Biologics chose the largest available single use bioreactors (4,000L), a hybrid single-use/stainless steel process design, and an integrated approach for process design, manufacturing, installation, and commissioning. The result is a highly flexible, large-scale process that was turned over only 28 months after start of design, with much of the project occurring during the COVID-19 crisis. In this talk, we provide details of the process scope as well as the project execution approach.